Why the study?
Does ventricular tachycardia ablation reduce VT-related events compared to escalated antiarrhythmic drug therapy in patients with prior myocardial infarction based on scar location?
Does ventricular tachycardia ablation reduce VT-related events compared to escalated antiarrhythmic drug therapy in patients with prior myocardial infarction based on scar location?
The benefit of VT ablation over escalated AAD therapy in ischemic cardiomyopathy may be driven primarily by patients with non-inferior MI scars.
VT ablation may be prioritized over AAD escalation for non-inferior MI scars; extends RCT evidence on scar location in ischemic VT.
The effectiveness of VT ablation versus escalated AADs varies based on the location of the MI. Patients with MI scars located only in non-inferior regions of the ventricles derive greater benefit from VT ablation in comparison to escalation of AADs in reducing VT-related events.
No takes yet. Share an insight, caveat, or question.
Samuel et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: